Role of Gene Editing in Rare Disease Management: Emerging Therapeutic Paradigms
International Journal of Innovative Science and Research Technology · 03.04.2026 · 3009
DOI: 10.38124/ijisrt/26mar1591 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Innovative Science and Research Technology, online erschienen am 03.04.2026. Verfasst von Mukesh Kumari. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Rare diseases, affecting millions globally despite their individual rarity, represent a major unmet medical challenge due to limited therapeutic options. Advances in gene-editing technologies—particularly CRISPR-Cas systems, base editing, and prime editing—have revolutionized the treatment paradigm from symptomatic management to potential curative interventions. This research paper explores the mechanistic basis, therapeutic applications, clinical progress, quantitative insights, and future directions of gene editing in rare disease management. It highlights emerging paradigms such as personalized gene therapy, in vivo editing, and RNA editing, while addressing ethical, regulatory, and economic challenges. The paper concludes that gene editing holds transformative potential but requires advancements in safety, accessibility, and scalability for widespread clinical adoption.
Zitieren
APA
Kumari, M. (2026). Role of Gene Editing in Rare Disease Management: Emerging Therapeutic Paradigms. International Journal of Innovative Science and Research Technology, 3009. https://doi.org/10.38124/ijisrt/26mar1591
Vancouver
Kumari M. Role of Gene Editing in Rare Disease Management: Emerging Therapeutic Paradigms. International Journal of Innovative Science and Research Technology. 2026:3009. doi:10.38124/ijisrt/26mar1591
BibTeX
@article{Kumari2026,
author = {Kumari, Mukesh},
title = {Role of Gene Editing in Rare Disease Management: Emerging Therapeutic Paradigms},
journal = {International Journal of Innovative Science and Research Technology},
year = {2026},
pages = {3009},
doi = {10.38124/ijisrt/26mar1591}
}
EUVIMED